|
The following is a list of research services available through CORL. If what you need is not listed, we can probably help you find it.
How much do services cost?
Clinical Comparative Ophthalmology
Clinical services include all aspects of ocular examination including slit lamp, ophthalmoscopy, tonometry, and photo documentation. Our veterinary ophthalmologists can perform routine ERG, provide ocular surgical support, and perform specialized ocular procedures as might be required in specialized testing protocols.
Fundus Evaluation
The mission of the Fundus Photograph Reading Center is to develop methods for assessment of ocular disorders and ocular manifestations of systemic disorders in Fundus and other ocular photographs that are suitable for multi-center clinical trials and epidemiologic studies, and to collaborate in the design, conduct, and analysis of such studies. This group of specialists includes ophthalmologists and highly trained technicians who photograph changes in the fundus with or without Fluorescein Angiography in such a way as to create a document of the fundus conditions in disease progression. These techniques are critical in the analysis of changes induced by laser protocols or intravitreous drug delivery especially when large organic compounds such as proteins or oligonucleatides are used.
Vitreoretinal Surgery
Dr. Nork is an Ophthalmologist with a specialty in vitreoretinal surgery and pathology. When the protocol calls for surgical techniques in the posterior segment Dr. Nork can help. He has expertise with both the primate laser induced glaucoma and chorioretinal neovascularization models.
Dr. Altaweel is an Assistant Professor of Ophthalmology at the UW Medical School. He specializes in diseases and surgery of the retina and vitreous and fundus interpretation. Dr. Altaweel is a co-director of the UW Department of Ophthalmology Fundus Photograph Reading Center. His research interests include clinical trials of drug efficacy as well as the scientific grading of retinal photographs and fluorescein angiograms.
Neuro protection
Dr. Levin, is a fellowship-trained board-certified Neuro-Ophthalmologist who specializes in diseas of the optic nerve. He also received a PhD in Neurobiology, and his laboratory studies optic neuropathies and retinal ganglion cell death at the molecular, biochemical, and cellular level. He has served as a consultant to pharmaceutical companies in the ares of neuroprotection and its application to human disease, including glaucoma.
Dr. Nickells is a Molecular Biologist who specializes in intracellular signaling pathways. His research utilizes the tools of molecular biology to investigate pathophysiologic processes of the retina and optic nerve. His current research focuses on glaucoma and neuroprotective mechanisms.
Dr. Nork is an Associate Professor of Ophthalmology at the UW Medical School. He has an NIH grant to study the effects of glaucoma on the outer retina (the photoreceptors) and possible neuroprotective mechanisms. This work incorporates a model of experimental gluacoma in monkeys. In addition to his own laboraty research, he works with the UW Department of Ophthalmology Fundus Photograph Reading Center on grading retina photographs related to toxicologic studies and provides expertise on retinal laser photocoagulation for animal models of choridal neovascularization and photic injury.
Ocular Immunology
Ocular Infection
Dr. Adnes' research focuses on examining the relationships between antimicrobial pharmacodynamics and drug resistance, and identifying new antimicrobial drug treatment strategies and drug targets using in-vitro and animal infection models. He also works with clients to develop animal models.
Dr. Brandt's research focuses is on ocular virology, specifically pathogenesis of herpes simplex virus; virulence genes in herpetic eye disease and herpes encephalitis; antivirals; interactions between cytokines and herpes viruses, and gene delivery, gene therapy. He also works with clients to develop animal models.
Ocular Physiology
Dr. Kaufman's research centers on studies seeking to understand the pathophysiology and development of new therapies for the human diseases of glaucoma and presbyopia.
Ocular Pharmacology
Dr. Edelhauser's primary research includes the pathogenesis of corneal edema after intraocular surgery, corneal and scleral permeability of therapeutic drugs to treat eye disease, ocular toxicology and development of new methods for transscleral drug delivery to the posterior segment.
Dr. Crosson's research interests include ischemia, neovascularization, and glaucoma. Current research in his laboratory includes pharmacological treatment of elevated intraocular pressure and the use of retinal as a probe of the structure and function of retinoid binding proteins.
Ocular Toxicology
Dr. Eells is a neurotoxicologist with recognized expertise in the mechanisms of retinal and optic nerve toxicity. Her laboratory utilizes molecular, biochemical and cellular approaches to investigate ocular toxicity. She also has considerable experience in the development and characterization of animal models of retinal and optic nerve toxicity and disease. Dr. Eells has served as an advisor and consultant to pharmaceutical companies, government agencies and the World Health Organization in the area of ocular toxicity.
Molecular Biology
Dr. Reid's investigations center on the molecular modulators of cellular proliferation in the eye. Dr. Reid has a particular interest in developing substances that might be useful as prosthetic materials in ocular therapy or testing.
Dr. Polans' research focuses on the role of calcium-binding proteins in cancer related diseases of the eye. These substances are related to neurodegeneration and cancer progression and they are of major interest in the areas of neuroprotection, cancer chemotherapy.
Dr. Nickells' work centers on cell death in retinal degeneration using retinoblastoma and glaucoma as models. This work is important in understanding retinal neurotoxicity, retinal neuroprotection, which are major considerations in glaucoma therapy and gene therapy, aimed at neuroprotection or recovery.
Dr. Auerbach's work is in vascular endothelial cell biology with a focus on endothelial cell differentiation and neovascularization. Dr. Auerbach's input would be important in developing studies of ocular neovascularization, which is of great interest in the fields of Age Related Macular Degeneration, Diabetic Retinopathy, Retinopathy of Prematurity, Ocular Inflammation, and Prosthetic Implants.
Dr. Bertics is a molecular biochemist with an interest in the biology of cellular signaling. Using the epithelial growth factor receptor and macrophage activation as models, he studies the determinants involved in specifying and regulating the function of receptor interaction and cellular activation. Techniques such as high throughput screening for cell signaling antagonists and rational drug design are so integral to the lab's specialties.
Dr. Sheibani is a molecular and cell biologist with an interest in mechanisms that keep angiogensis in check and how their alterations under pathological conditions, such as ischemia or diabetes, results in neovascularization. He has developed a number of in vivo (developing retinal vasculature, oxygen-induced ischemic retinopathy, diabetes) and in vitro (endothelial cells proliferation, migration, and capillary formation) models to study these mechanisms. This knowledge will be instrumental in design of agonists and/or antagonists that modulate angiogenesis.
Cornea/Anterior Segment
Christopher J. Murphy, D.V.M., Ph.D., Dipl. ACVO: Dr. Murphy is a Veterinary Ophthalmologist with research and corneal fellowship training. His interests are in wound healing, the interaction of cells with biomaterials, improved methods of organ preservation, and comparative physiological optics. His lab is funded to investigate factors affecting corneal epithelial differentiation, adhesion, migration, and proliferation. He manages a strong interdisciplinary laboratory fully equipped for state of the art cell and molecular biology studies. His lab routinely performs primary culture of a number of ocular cell types and conducts in vitro cytotoxicity assays.
Neal Barney, M.D.: Dr. Barney is a board certified Ophthalmologist who is an Associate Professor in the Department of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine. He is the director of the cornea service at UW-Madison Eye Clinic. His specialty training is in all aspects of anterior segment medicine and surgery with a particular emphasis on ocular immunology. His laboratory interests include the cellular signaling events on the ocular surface undergoing allergic reactions. He serves on the editorial board of Investigative Ophthalmology and Visual Sciences, as grant reviewer for Fight for Sight, and is the principle investigator for NIH funded research.
Regulatory Affairs
Charles O’Neill provides consulting services to CORL clients on regulatory strategies, tactics and processes for developers and manufacturers of ophthalmic medical devices, drugs, and biologics.
Charles brings to CORL 14 years of biotechnology and pharmaceutical development experience. Dr. O'Neill led nonclinical development efforts regarding anti-angiogenic molecules including the targeted oncology monoclonal antibody AvastinTM, and the intra-vitreally delivered monoclonal antibody fragment LucentisTM a treatment for the neovascular form of age-related macular degeneration. Regarding the LucentisTM nonclinical development, Dr. O'Neill designed, implemented and analyzed nonclinical pharmacology and toxicology studies demonstrating the safety, dosing schedules, dosing levels and pharmacological activity of LucentisTM in various animal models and interacted with regulatory agencies regarding this nonclinical development. Currently, Dr. O'Neill is Assistant Adjunct Professor in the Pharmacology and Toxicology Graduate Group at UC Davis. Dr. O'Neill was a Postdoctoral Fellow at the NIH, NHLBI. Dr. O'Neill has contributed to 26 regulatory submissions in the US, EU, Australia and Japan and has coauthored over 40 peer-reviewed publications. Dr. O'Neill received his Ph.D. in Pharmacology and Toxicology from UC Davis in 1992 and has been a Diplomate of the American Board of Toxicology since 1995.
Animal Models: In vivo models available to industry
Members of CORL have experience with a wide array of animal models of value to identification and development of lead therapeutic compounds. Below is a partial list of the models available. If the model you are interested in is not listed, please call as it very possible that one of our members has expertise in it.
CORL members have experience with the following in vivo models:
- Ocular Vascularization
- Laser induced choroidal neovascularization (CNV)
- Rodent models for CNV
- Rodent models for retinopathy of prematurity (ROP)
- Corneal wound healing
- Laser induced glaucoma
- Rodent models for ocular cancer
- Rodent models for delayed skin wound healing
Go to top
|
